Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Clinton Foundation Reaches Deal With Matrix, Pfizer to Cut Prices for Second-Line ARVs, TB Drug

August 7, 2009

Former President Bill Clinton on Thursday announced deals with drugmakers Matrix Laboratories and Pfizer to lower the cost of medications to treat patients with drug-resistant HIV in the developing world, Reuters reports (Honan, 8/6).

The agreement between the Clinton Foundation and Matrix (a subsidiary of Mylan) will lower the annual price of four second-line antiretrovirals -- atazanavir, ritonavir, tenofovir and lamivudine  -- to $425 next year, and "the pills will be packaged together and sold as something patients can take once a day," the Associated Press/Seattle Times reports. The foundation says the 2010 cost for the four drugs "is 28 percent lower than the current lowest-priced alternative" (Hajela, 8/6). As part of the deal, Matrix will also "make ritonavir available in a heat-stable version more suitable for tropical climates," the Financial Times writes (Jack, 8/7). "If fully adopted the new regimen could lead to a cumulative cost savings of $400 million over the next five years compared with recent prices for alternative treatments," the Wall Street Journal writes (Stynes, 8/6).

Pfizer has agreed with the foundation to sell its "tuberculosis drug rifabutin at $1 per dose, a 60 percent price decrease, or $90 for a full, six-month treatment," the AP/Seattle Times writes. Unlike other TB treatments, "rifabutin does not have the same interactions with the second-line [ARV] drugs" (8/6).

Advertisement
"Today's announcement will help ensure we can sustain treatment over a lifetime and better treat patients with both HIV and TB, two key steps in turning the tide of the global HIV/AIDS pandemic," Clinton said, according to a press release (8/6).

Agence France-Presse reports that the reduced-cost HIV drugs will be available "to governments taking part in the Clinton Foundation's Procurement Consortium across Africa, Asia, Latin America and the Caribbean."  The lower price for rifabutin "will be available throughout developing markets in Africa, Asia, Eastern Europe, Latin America, the Middle East and the Caribbean" (8/6).

Back to other news for August 2009


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More News and Analysis on HIV Drug Pricing
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement